Key facts
- Oncomatryx Biopharma’s last known valuation is $111.8M (Mar 2022).
- It has raised $146.0M; the latest was PE Growth/Expansion ($67.6M) in Mar 2026.
- Notable investors include European Innovation Council, INNVIERTE SICC, Basque Government, Bilbao Bizkaia Kutxa, Diputación Foral de Bizkaia — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Oncomatryx Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Oncomatryx Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oncomatryx Biopharma
Developer of stroma-targeted precision drugs and diagnostics intended to fight against invasive tumours. The company is aimed at discovering new mechanisms and proteins in the peritumoral stroma, the cells, and the extracellular matrix that surround the tumour and facilitate its invasiveness, resistance to treatment, and metastasis, enabling doctors to diagnose, prognosis, and fight against tumour invasiveness.
- Sector
- Healthcare
- HQ
- Derio, Spain
- Founded
- 2009
- Employees
- 36
- Website
- oncomatryx.com/
- Ownership
- Privately Held (backing)
Oncomatryx Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oncomatryx Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oncomatryx Biopharma in its N-PORT filings yet. We sweep new filings monthly.